Hantaviruses pp 171-191 | Cite as

Vaccines Against Hantaviruses

  • J. W. Hooper
  • D. Li
Part of the Current Topics in Microbiology and Immunology book series (CT MICROBIOLOGY, volume 256)


Hantaviruses are associated with two human diseases: hemorrhagic fever with renal syndrome (HFRS) and hantavirus pulmonary syndrome (HPS). These viruses are carried by persistently infected rodents, and are transmitted to humans by aerosolized rodent excreta. HFRS is characterized by fever, hemorrhagic manifestations, renal dysfunction, and shock. HPS is characterized by fever, headache, myalgia, and gastrointestinal symptoms, followed by noncardiogenic pulmonary edema, and shock. Although there are orders of magnitude fewer HPS cases than HFRS cases, the small outbreaks of HPS that have occurred have been highly lethal, with case-fatality rates of 40-60%. In addition, there is evidence that at least one of the HPS hantaviruses can be transmitted from person-to-person (Wells et al. 1997). Since 1993, 555 HPS cases have been reported in the United States, Canada, and several countries in South America. Recently, for the first time, a hantavirus was associated with an outbreak of lethal acute febrile respiratory illness in Central America (Bayard et al. 2000). A summary of hantaviruses that are known to cause human disease are shown in Table 1.


Bank Vole Hemorrhagic Fever With Renal Syndrome Neutralize Antibody Response Geometric Mean Titer Nephropathia Epidemica 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Ahn CN (1997) Hemorrhagic fever with renal syndrome (HFRS) vaccine in Korea WHO working group on prevention and control of Hantavirus infections. (Abstract) Seoul 5–6 Nov 1997Google Scholar
  2. Arikawa J, Yao JS, Yoshimatsu K, Takashima I, Hashimoto N (1992) Protective role of antigenic sites on the envelope protein of Hantaan virus defined by monoclonal antibodies. Arch Virol 126, 271–281PubMedCrossRefGoogle Scholar
  3. Bayard V, et al. (2000) Hantavirus pulmonary syndrome: Panama, 1999–2000. MMWR 49:205–207Google Scholar
  4. Bharadwaj M, Lyons RC, Wortman IA, Hjelle B (1999) Intramuscular inoculation of Sin Nombre hantavirus cDNAs induces cellular and humoral immune responses in BALB/c mice. Vaccine 17:2836–2843PubMedCrossRefGoogle Scholar
  5. Chen HX, Luo ZZ, Zhang JJ (1999) Study on epidemiological efficacy and immunologic strategy of vaccines against hemorrhagic fever with renal syndrome Chinese Public Health 15:561–8 (in Chinese)Google Scholar
  6. Cho HW, Howard CR (1999) Antibody responses in humans to an inactivated hantavirus vaccine (Hantavax) Vaccine 4:2569–75Google Scholar
  7. Chu YK, Jennings GB, Schmaljohn CS (1995) A vaccinia virus-vectored Hantaan virus vaccine protects hamsters from challenge with Hantaan and Seoul viruses but not Puumala virus. J Virol 69:6417–6423PubMedGoogle Scholar
  8. Dong GM, An Q, Zhu ZY (1998) Expanded human trail of the bivalent HFRS inactivated vaccine made from M. gerbil kidney tissue culture. Chin J Microbiol Immunol 18:453–456Google Scholar
  9. Dubensky T, Driver D, Polo J, Belli B, Latham E, Ibanex C, Chada S, Brumm D, Banks T, Mento S, Jolly D, Chang S (1996) Sindbis virus DNA-based expression vectors: utility for in vitro and in vivo gene therapy. J Virol 70:508–519PubMedGoogle Scholar
  10. Frolov I, Hoffman TA, Pragai BM, Dryga SA, Huang HV, Schlesginer S, Rice CM (1996) Alphavirus-based expression vectors: strategies and applications. Proc Natl Sci USA 93:11 371–11 377Google Scholar
  11. Hao FY, Hui LG, Zhao XL, Wang XH, Han L, Huang YC (1996) Efficacy test for inactivated epidemic hemorrhage fever vaccine using golden hamsters. Chin J Biol 9:69–72 (in Chinese)Google Scholar
  12. Hooper JW, Kamrud KI, Elgh F, Custer D, Schmaljohn CS (1999) DNA vaccination with hantavirus M segment elicits neutralizing antibodies and protects against Seoul virus infection. Virology 255: 269–278PubMedCrossRefGoogle Scholar
  13. Kamrud KI, Hooper JW, Elgh F, Schmaljohn CS (1999) Comparison of protective efficacy of naked DNA, DNA-based replicon, and packaged Sindbis replicon vectors expressing hantavirus structural genes in hamsters. Virology 263:209–219PubMedCrossRefGoogle Scholar
  14. Kim RJ, Ru C, Kim GM (1991) The special prevention of HFRS in P.D.R of Korea. Chinese Clin Exper Virol 4:487–92 (in Chinese)Google Scholar
  15. Lee H, Ahn C, Song J, Baek L, Seo T, Park S (1990) Field trial of an inactivated vaccine against hemorrhagic fever with renal syndrome in humans. Arch Virol (Suppl 1):35–47Google Scholar
  16. Liu PQ, Liao HX, Fu JL (1984) Isolation of epidemic hemorrhagic fever viruses from Rattus losea and R. Confucianus, and their antigenic identification. Bull Jiangxi Med Coll 3:1 (in Chinese)Google Scholar
  17. Liu WM, Song G, Zhang QF (1992) Comparative studies on inactivating methods for production of inactivated cell culture vaccine against epidemic hemorrhagic fever. Chin J Virol 3:141–146 (in Chinese)Google Scholar
  18. Lundkvist Å, Kallio-Kokko H, Brus-Sjölander K, Lankinen H, Niklasson B, Vaheri A, Vapalahti O (1996) Characterization of Puumala virus nucleocapsid protein: identification of B-cell epitopes and domains involved in protective immunity. Virology 216:397–406PubMedCrossRefGoogle Scholar
  19. McClain DJ, Summers PL, Harrison SA, Schmaljohn AL, Schmaljohn CS (2000) Clinical evaluation of a vaccinia-vectored Hantaan virus vaccine. J Med Virol 60:77–85PubMedCrossRefGoogle Scholar
  20. Oya A (1976) Japanese encephalitis vaccine: the vaccination. Int Medical Found Japan 1976:69–72Google Scholar
  21. Pensiero MN, Jennings GB, Schmaljohn CS, Hay J (1988) Expression of the Hantaan virus M genome segment by using a vaccinia virus recombinant. J Virol 62:696–702PubMedGoogle Scholar
  22. Ren K, Lu QX, Song G, Huang YC, Sun RH, Wang S (1996) Serological efficacy of the inactivated golden hamster kidney cell vaccine against hemorrhagic fever with renal syndrome in human trial. Chin J Exp Clin Virol 10:10–15 (in Chinese)Google Scholar
  23. Robinson HL, Torres CA (1997) DNA vaccines. Semin Immunol 9:271–283PubMedCrossRefGoogle Scholar
  24. Schmaljohn CS (1996) Molecular Biology of Hantaviruses. In: Elliott RM (ed) The Bunyaviridae. New York, Plenum Press pp 63–90Google Scholar
  25. Schmaljohn CS, Chu YK, Schmaljohn AL, Dalrymple JM (1990) Antigenic subunits of Hantaan virus expressed by baculovirus and vaccinia virus recombinants. J Virol 64:3162–3170PubMedGoogle Scholar
  26. Schmaljohn CS, Hasty SE, Dalrymple JM (1992) Preparation of candidate vaccinia-vectored vaccines for haemorrhagic fever with renal syndrome. Vaccine 10:10–13PubMedCrossRefGoogle Scholar
  27. Smadel JE (1953) Epidemic hemorrhagic fever. Am J Pub Hlth 43:13327–13335Google Scholar
  28. Ulrich R, Lundkvist Å, Meisel H, Koletzki D, Brus Sjölander K, Gelderblom HR, Borisova G, Schnitzler P, Darai G, Kruger DH (1998) Chimaeric HBV core particles carrying a defined segment of Puumala hantavirus nucleocapsid protein evoke protective immunity in an animal model. Vaccine 16:272–280PubMedCrossRefGoogle Scholar
  29. Ulrich R, Koletzki H, Lachmann S, Lundkvist Å, Zankl A, Kazaks A, Kurth A, Gelderblom R, Borisova G, Meisel H, Kruger DH (1999) New chimaeric hepatitis B virus core particles carrying hantavirus (serotype Puumala) epitopes: immunogenicity and protection against virus challenge. J Biotechnol 73:141–153PubMedCrossRefGoogle Scholar
  30. Wells RM, Sosa Estani S, Yadon ZE, Enria D, Padula P, Pini N, Mills JN, Peters CJ, Segura EL (1997) An unusual hantavirus outbreak in southern Argentina: person-to-person transmission? Hantavirus Pulmonary Syndrome Study Group for Patagonia. Emerg Infect Dis Apr-Jun3:171–174CrossRefGoogle Scholar
  31. Xu X, Ruo SL, McCormick JB, Fisher-Hoch SP (1992) Immunity to Hantavirus challenge in Meriones unguiculatus induced by vaccinia-vectored viral proteins. Am J Trop Med Hyg 47:397–404PubMedGoogle Scholar
  32. Yamanishi K, Tanishita O, Tamura M, Asada H, Kondo K, Takagi M, Yoshida I, Konobe T, Fukai K (1988) Development of inactivated vaccine against virus causing haemorrhagic fever with renal syndrome. Vaccine 3:278–282CrossRefGoogle Scholar
  33. Yoshimatsu K, Yoo YC, Yoshida R, Ishihara C, Azuma I, Arikawa J (1993) Protective immunity of Hantaan virus nucleocapsid and envelope protein studied using baculovirus expressed proteins. Arch Virol 130:365–376PubMedCrossRefGoogle Scholar
  34. Yu YX, Yao XJ, Dong GM, An Q, Li ZP (1990) Antibody response of inactivated HFRS vaccine to homologous and heterologous types of the virus. Chin J Biol 3:14–16Google Scholar
  35. Yu YX, Liu WX, Nei ZL (1992) Neutralizing antibody response in humans immunized with Meriones gerbil kidney tissue culture inactivated HFRS vaccine assesed by two methods. Virol Sin 7:176–180Google Scholar
  36. Zhu ZY, Zeng RF, Yu XY (1991) Efficacy of inactivated EHF vaccine in clinical trial. Virol Sin 6: 315–319Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2001

Authors and Affiliations

  • J. W. Hooper
    • 1
  • D. Li
    • 2
  1. 1.Virology DivisionUnited States Army Medical Research Institute for Infectious DiseasesFort DetrickUSA
  2. 2.Institute of VirologyChinese Academy of Preventive MedicineXuan Wu QuChina

Personalised recommendations